{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:51:01Z","timestamp":1791456661653,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aldosterone, a key component of the renin\u2013angiotensin\u2013aldosterone system (RAAS), plays a central role in sodium balance, vascular tone, blood pressure control, and cardiovascular remodeling. Dysregulation of aldosterone mechanism, including excessive production, deficiency, and inappropriate receptor activation, represents a significant contributor to cardiovascular and renal disease which is often underrecognized. Aldosterone dysregulation may manifest as primary aldosteronism that is increasingly identified as a common cause of secondary hypertension, or by secondary hyperaldosteronism that reflects maladaptive responses in common clinical conditions such as heart failure and liver cirrhosis. Conversely, hypoaldosteronism, particularly in diabetic nephropathy, predisposes to hyperkalemia and metabolic acidosis. Furthermore, aldosterone dysregulation can be observed in many clinically important and common patient phenotypes such as older patients, obese, and patients with diabetes where the elevated levels of aldosterone can contribute to poor blood pressure control and development of target organ damage particularly at the cardiac, vascular, and renal level. Beyond circulating levels of aldosterone itself, mineralocorticoid receptor (MR) overactivation in the absence of elevated aldosterone highlights the complexity of tissue-specific signaling. This review summarizes the spectrum of aldosterone dysregulation, delineates key patient phenotypes, and discusses diagnostic and therapeutic implications with a focus on cardiovascular outcomes. Recognizing aldosterone dysregulation as a systemic cardio\u2013renal\u2013metabolic disorder has important implications for risk stratification and targeted therapies.<\/jats:p>","DOI":"10.1093\/ajh\/hpag082","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:39:46Z","timestamp":1784029186000},"page":"S11-S17","source":"Crossref","is-referenced-by-count":0,"title":["Pathophysiology of aldosterone dysregulation in difficult-to-control hypertension"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-0042","authenticated-orcid":false,"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo F G","family":"Cicero","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806020630500_hpag082-B1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806020630500_hpag082-B2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","article-title":"Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers","volume":"20","author":"Gordon","year":"1993","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026100806020630500_hpag082-B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026100806020630500_hpag082-B4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.126.26235","article-title":"Role of mineralocorticoid receptors in cardiovascular disease","volume":"84","author":"Elton-Bott","year":"2026","journal-title":"Hypertension"},{"key":"2026100806020630500_hpag082-B5","doi-asserted-by":"publisher","first-page":"31283","DOI":"10.1074\/jbc.M504098200","article-title":"A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor","volume":"280","author":"Bledsoe","year":"2005","journal-title":"J Biol Chem"},{"key":"2026100806020630500_hpag082-B6","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1046\/j.1523-1755.2000.00980.x","article-title":"Specific nongenomic actions of aldosterone","volume":"57","author":"Falkenstein","year":"2000","journal-title":"Kidney Int"},{"key":"2026100806020630500_hpag082-B7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2026100806020630500_hpag082-B8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"2026100806020630500_hpag082-B9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/hypertensionaha.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal disease","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"2026100806020630500_hpag082-B10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1373\/clinchem.2004.041780","article-title":"Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity","volume":"51","author":"Schwartz","year":"2005","journal-title":"Clin Chem"},{"key":"2026100806020630500_hpag082-B11","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026100806020630500_hpag082-B12","first-page":"220","article-title":"Aldosterone-to-renin ratio as a screening test for primary aldosteronism: the Dutch ARRAT study","volume":"66","author":"Jansen","year":"2008","journal-title":"Neth J Med"},{"key":"2026100806020630500_hpag082-B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"2026100806020630500_hpag082-B14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/00004872-200201000-00017","article-title":"Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension","volume":"20","author":"Schlaich","year":"2002","journal-title":"J Hypertens"},{"key":"2026100806020630500_hpag082-B15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","article-title":"Aldosterone and refractory hypertension: a prospective cohort study","volume":"19","author":"Sartori","year":"2006","journal-title":"Am J Hypertens"},{"key":"2026100806020630500_hpag082-B16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"2026100806020630500_hpag082-B17","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin\u2013angiotensin\u2013aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"2026100806020630500_hpag082-B18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/j.1552-4604.1993.tb03901.x","article-title":"Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors","volume":"33","author":"Borghi","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"2026100806020630500_hpag082-B19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MNH.0b013e3282f56854","article-title":"Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation","volume":"17","author":"Young","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026100806020630500_hpag082-B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjhyper.2005.05.013","article-title":"Role of aldosterone in left ventricular hypertrophy in hypertension","volume":"19","author":"Matsumura","year":"2006","journal-title":"Am J Hypertens"},{"key":"2026100806020630500_hpag082-B21","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.amjhyper.2006.02.002","article-title":"Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension","volume":"19","author":"Strauch","year":"2006","journal-title":"Am J Hypertens"},{"key":"2026100806020630500_hpag082-B22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.amjhyper.2004.08.026","article-title":"Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"},{"key":"2026100806020630500_hpag082-B23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026100806020630500_hpag082-B24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026100806020630500_hpag082-B25","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026100806020630500_hpag082-B26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"2026100806020630500_hpag082-B27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"key":"2026100806020630500_hpag082-B28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026100806020630500_hpag082-B29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res"},{"key":"2026100806020630500_hpag082-B30","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/hypertensionaha.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","volume":"57","author":"Lother","year":"2011","journal-title":"Hypertension"},{"key":"2026100806020630500_hpag082-B31","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1002\/j.2040-4603.2023.tb00256.x","article-title":"Aldosterone: renal action and physiological effects","volume":"13","author":"Johnston","year":"2023","journal-title":"Compr Physiol"},{"key":"2026100806020630500_hpag082-B32","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41440-026-02561-4","article-title":"Aldosterone -mineralocorticoid receptor interactions: new insights and therapeutic perspectives in primary aldosteronism","volume":"49","author":"Yoshida","year":"2026","journal-title":"Hypertens Res"},{"key":"2026100806020630500_hpag082-B33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamacardio.2026.0068","article-title":"Spectrum of primary aldosteronism and risk of cardiovascular outcomes: the atherosclerosis risk in communities study","volume":"11","author":"Lassen","year":"2026","journal-title":"JAMA Cardiol"},{"key":"2026100806020630500_hpag082-B34","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"2026100806020630500_hpag082-B35","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/bcp.15156","article-title":"Effect of diuretics on plasma aldosterone and potassium in primary hypertension: a systematic review and meta-analysis","volume":"88","author":"McNally","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026100806020630500_hpag082-B36","volume-title":"StatPearls","author":"Polycarpe","year":"2026"},{"key":"2026100806020630500_hpag082-B37","doi-asserted-by":"publisher","first-page":"T107","DOI":"10.1530\/JOE-16-0659","article-title":"30 Years of the mineralocorticoid receptor: Nongenomic effects via the mineralocorticoid receptor","volume":"234","author":"Ruhs","year":"2017","journal-title":"J Endocrinol"},{"key":"2026100806020630500_hpag082-B38","doi-asserted-by":"publisher","first-page":"e038644","DOI":"10.1161\/JAHA.124.038644","article-title":"Journal of the American heart association. Heart disease mortality in the United States, 1970 to 2022","volume":"14","author":"King","year":"2025","journal-title":"J Am Heart Assoc"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S11\/71667125\/hpag082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S11\/71667125\/hpag082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:02:15Z","timestamp":1791453735000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/Supplement_1\/S11\/8875944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":38,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag082","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]}}}